Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Depressive symptoms and cortisol rhythmicity predict survival in patients with renal cell carcinoma: role of inflammatory signaling.

Cohen L, Cole SW, Sood AK, Prinsloo S, Kirschbaum C, Arevalo JM, Jennings NB, Scott S, Vence L, Wei Q, Kentor D, Radvanyi L, Tannir N, Jonasch E, Tamboli P, Pisters L.

PLoS One. 2012;7(8):e42324. doi: 10.1371/journal.pone.0042324.

2.

Diurnal cortisol rhythm as a predictor of lung cancer survival.

Sephton SE, Lush E, Dedert EA, Floyd AR, Rebholz WN, Dhabhar FS, Spiegel D, Salmon P.

Brain Behav Immun. 2013 Mar;30 Suppl:S163-70. doi: 10.1016/j.bbi.2012.07.019.

PMID:
22884416
3.

Diurnal cortisol rhythm as a predictor of breast cancer survival.

Sephton SE, Sapolsky RM, Kraemer HC, Spiegel D.

J Natl Cancer Inst. 2000 Jun 21;92(12):994-1000.

4.

Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.

Volpe A, Novara G, Antonelli A, Bertini R, Billia M, Carmignani G, Cunico SC, Longo N, Martignoni G, Minervini A, Mirone V, Simonato A, Terrone C, Zattoni F, Ficarra V; Surveillance and Treatment Update on Renal Neoplasms (SATURN) Project.; Leading Urological No-Profit Foundation for Advanced Research (LUNA) Foundation..

BJU Int. 2012 Jul;110(1):76-83. doi: 10.1111/j.1464-410X.2011.10690.x.

5.

Salivary cortisol and depression in public sector employees: cross-sectional and short term follow-up findings.

Vammen MA, Mikkelsen S, Hansen ÅM, Grynderup MB, Andersen JH, Bonde JP, Buttenschøn HN, Kolstad HA, Kærgaard A, Kærlev L, Mors O, Rugulies R, Thomsen JF.

Psychoneuroendocrinology. 2014 Mar;41:63-74. doi: 10.1016/j.psyneuen.2013.12.006.

PMID:
24495608
6.
7.

Caveolin 1 protein expression in renal cell carcinoma predicts survival.

Steffens S, Schrader AJ, Blasig H, Vetter G, Eggers H, Tränkenschuh W, Kuczyk MA, Serth J.

BMC Urol. 2011 Dec 7;11:25. doi: 10.1186/1471-2490-11-25.

8.

Depression, immunity, and survival in patients with hepatobiliary carcinoma.

Steel JL, Geller DA, Gamblin TC, Olek MC, Carr BI.

J Clin Oncol. 2007 Jun 10;25(17):2397-405.

PMID:
17557953
9.

Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.

Vasselli JR, Yang JC, Linehan WM, White DE, Rosenberg SA, Walther MM.

J Urol. 2001 Jul;166(1):68-72.

PMID:
11435825
10.

Renal sinus fat invasion in pT3a clear cell renal cell carcinoma affects outcomes of patients without nodal involvement or distant metastases.

Bertini R, Roscigno M, Freschi M, Strada E, Petralia G, Pasta A, Matloob R, Sozzi F, Da Pozzo L, Colombo R, Guazzoni G, Doglioni C, Montorsi F, Rigatti P.

J Urol. 2009 May;181(5):2027-32. doi: 10.1016/j.juro.2009.01.048.

PMID:
19286201
11.

Inflammatory prognostic markers in clear cell renal cell carcinoma - preoperative C-reactive protein does not improve predictive accuracy.

Bedke J, Chun FK, Merseburger A, Scharpf M, Kasprzyk K, Schilling D, Sievert KD, Stenzl A, Kruck S.

BJU Int. 2012 Dec;110(11 Pt B):E771-7. doi: 10.1111/j.1464-410X.2012.11642.x.

12.

Factors affecting survival in 37 consecutive patients undergoing de novo stereotactic radiosurgery for contiguous sites of vertebral body metastasis from renal cell carcinoma.

Sellin JN, Reichardt W, Bishop AJ, Suki D, Rhines LD, Settle SH, Brown PD, Li J, Rao G, Chang EL, Tatsui CE.

J Neurosurg Spine. 2015 Jan;22(1):52-9. doi: 10.3171/2014.9.SPINE1482.

PMID:
25360530
13.

Independent value of tumor size and DNA ploidy for the prediction of disease progression in patients with organ-confined renal cell carcinoma.

Di Silverio F, Casale P, Colella D, Andrea L, Seccareccia F, Sciarra A.

Cancer. 2000 Feb 15;88(4):835-43.

PMID:
10679653
14.

Plasma matrix metalloproteinase-7 as a metastatic marker and survival predictor in patients with renal cell carcinomas.

Ramankulov A, Lein M, Johannsen M, Schrader M, Miller K, Jung K.

Cancer Sci. 2008 Jun;99(6):1188-94. doi: 10.1111/j.1349-7006.2008.00802.x.

15.

Prognostic prediction in patients with metastatic renal cell carcinoma treated with sorafenib based on expression levels of potential molecular markers in radical nephrectomy specimens.

Kusuda Y, Miyake H, Behnsawy HM, Fukuhara T, Inoue TA, Fujisawa M.

Urol Oncol. 2013 Jan;31(1):42-50. doi: 10.1016/j.urolonc.2010.09.008.

PMID:
21396851
16.
17.

Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma.

Lam JS, Shvarts O, Said JW, Pantuck AJ, Seligson DB, Aldridge ME, Bui MH, Liu X, Horvath S, Figlin RA, Belldegrun AS.

Cancer. 2005 Jun 15;103(12):2517-25.

18.

Glucose-regulated protein 78 positivity as a predictor of poor survival in patients with renal cell carcinoma.

Kuroda K, Horiguchi A, Asano T, Ito K, Asakuma J, Sato A, Yoshii H, Hayakawa M, Sumitomo M, Asano T.

Urol Int. 2011;87(4):450-6. doi: 10.1159/000330883.

PMID:
22076227
19.

High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma.

Parker AS, Kosari F, Lohse CM, Houston Thompson R, Kwon ED, Murphy L, Riehle DL, Blute ML, Leibovich BC, Vasmatzis G, Cheville JC.

Cancer. 2006 Jul 1;107(1):37-45.

20.

Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas.

Klatte T, Patard JJ, de Martino M, Bensalah K, Verhoest G, de la Taille A, Abbou CC, Allhoff EP, Carrieri G, Riggs SB, Kabbinavar FF, Belldegrun AS, Pantuck AJ.

J Urol. 2008 May;179(5):1719-26. doi: 10.1016/j.juro.2008.01.018.

PMID:
18343437
Items per page

Supplemental Content

Support Center